Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Asthma Step Therapy Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentZing HealthPolicy 4659-D

    Medicare Part B Step Therapy Asthma

    Customize your policy alerts

    Sign up for zing_health Policy 4659-D alerts

    Get alerted when Policy 4659-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of preferred and non-preferred asthma biologic products billed under Medicare Part B for Zing Health members. Non-preferred Cinqair and Nucala require clinical exception criteria through prior authorization, while preferred products may still require clinical prior authorization.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Asthma
    Policy CodePolicy 4659-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when seeking an exception to preferred-product step therapy for a non-preferred asthma product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3preferred asthma products
    2non-preferred products subject to step therapy
    365 daysprior-treatment lookback
    30 IU/mLserum IgE threshold
    Medicare Part B

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    applicable benefit

    Applicable Coverage Criteria

    Applicable Indication

    The program applies when the requested treatment is for an indication that is FDA-approved for the preferred products.

    FDA-approved indication: The requested treatment is for an indication that is FDA-approved for the preferred products.

    Cinqair Coverage

    Coverage for Cinqair is provided when either of the following criteria is met.

    Cinqair coverage pathways

    • Recent Cinqair treatment: Member has received treatment with Cinqair in the past 365 days.past 365 days
    • Preferred-product exception

      • Failure or intolerance of Fasenra and Tezspire: Documented inadequate response or intolerable adverse event with both preferred products, Fasenra and Tezspire.both products
      • IgE/Xolair pathway

        • IgE at least 30 IU/mL with Xolair failure or intolerance: Pretreatment serum IgE is at least 30 IU/mL and the member has documented inadequate response or intolerable adverse event with Xolair.at least 30 IU/mL
        • IgE less than 30 IU/mL: Pretreatment serum IgE is less than 30 IU/mL.less than 30 IU/mL

    Nucala Coverage

    Coverage for Nucala is provided when either of the following criteria is met.

    Nucala coverage pathways

    • Recent Nucala treatment: Member has received treatment with Nucala in the past 365 days.past 365 days
    • Nucala clinical exception

      • Nasal polyps pathway

        • IgE/Xolair pathway

          • IgE at least 30 IU/mL with Xolair failure or intolerance: Pretreatment serum IgE is at least 30 IU/mL and the member has documented inadequate response or intolerable adverse event with Xolair.at least 30 IU/mL

    Clinical Thresholds and Timing

    Pretreatment serum IgE
    IgE threshold 1Pretreatment serum IgE of at least 30 IU/mL
    IgE threshold 2Pretreatment serum IgE of less than 30 IU/mL
    Where appliedUsed in the Cinqair and Nucala clinical exception pathways
    Prior treatment lookback
    Lookback periodWithin the past 365 days
    Qualifying useTreatment with the requested non-preferred product—Cinqair or Nucala—within the lookback period
    DocumentationDocument prior treatment when relying on previous use

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization for Non-Preferred Products

    Submit a clinical prior authorization request when treatment with a non-preferred asthma product is requested. Coverage may be considered when clinical circumstances exclude use of the preferred products or when the member’s previous treatment history supports an exception.

    • Applies to non-preferred Cinqair (reslizumab) and Nucala (mepolizumab).
    • Document the applicable exception criteria and supporting clinical records with the request.
    Prior Authorization

    Preferred Products May Require Review

    Preferred products may still require clinical prior authorization review. Follow all applicable plan review and submission requirements even when requesting a preferred product.

    • Preferred products: Fasenra, Tezspire, and Xolair.

    Policy Scope

    This policy applies to asthma products billed under Medicare Part B when treatment is requested for an indication that is FDA-approved for the preferred products. It establishes a preferred-product sequence in which Fasenra, Tezspire, and Xolair are used before the non-preferred products Cinqair and Nucala, unless the member qualifies for a clinical exception.

    Non-preferred products are reviewed through prior authorization when clinical circumstances exclude use of the preferred products or when the member has qualifying previous use. This step therapy program applies in addition to applicable National Coverage Determinations, Local Coverage Determinations, and Medicare Part B utilization management programs. Preferred products may also require clinical prior authorization review under the plan.

    Utilization Management Terms

    Step therapy
    DefinitionA utilization management approach requiring use of designated preferred products before coverage of a non-preferred product, unless an approved clinical exception applies
    Preferred productsFasenra, Tezspire, and Xolair
    Non-preferred productsCinqair and Nucala
    Clinical exception
    DefinitionA coverage exception based on clinical circumstances that exclude use of preferred products
    Clinical supportMay include documented inadequate response or an intolerable adverse event with preferred products
    Previous treatment

    Initial Therapy for Non-Preferred Products

    Cinqair

    Coverage for Cinqair is provided when either of the following criteria is met.

    Cinqair initial coverage

    • Recent Cinqair treatment: Member has received treatment with Cinqair in the past 365 days.past 365 days
    • Preferred-product failure or intolerance with qualifying IgE pathway

      • Failure or intolerance of Fasenra and Tezspire: Documented inadequate response or intolerable adverse event with both preferred products, Fasenra and Tezspire.both products
      • IgE/Xolair pathway

    Continuation or Recent-Use Pathway

    Continuation or Recent-Use Pathway

    Coverage is available when the member has received the requested non-preferred product within the past 365 days.

    Recent use of requested product: Member has received treatment with the requested product, Cinqair or Nucala, in the past 365 days.past 365 days

    Preferred-Product Sequencing

    StepProductsRequirementCoverage
    1Preferred: Fasenra, Tezspire, and Xolair; non-preferred: Cinqair and NucalaUse the preferred products before requesting a non-preferred product, unless the member qualifies for a clinical exception.Preferred-product step required
    StepProductQualifying pathwayCoverage
    2CinqairEither: (1) the member received Cinqair within the past 365 days; or (2) the member has documented inadequate response or an intolerable adverse event with both Fasenra and Tezspire, and either has pretreatment serum IgE of at least 30 IU/mL with documented inadequate response or an intolerable adverse event with Xolair, or has pretreatment serum IgE less than 30 IU/mL.Covered when either pathway is met
    StepProductQualifying pathwayCoverage
    2NucalaEither: (1) the member received Nucala within the past 365 days; or (2) the member meets a clinical exception pathway. The clinical exception pathways are: nasal polyps with either pretreatment serum IgE of at least 30 IU/mL and documented inadequate response or an intolerable adverse event with Xolair, or pretreatment serum IgE less than 30 IU/mL; or both an applicable age/preferred-product criterion and an IgE or EGPA criterion. The age/preferred-product criterion is either age 12 years or older with documented inadequate response or an intolerable adverse event with both Fasenra and Tezspire, or under age 12 with documented inadequate response or an intolerable adverse event with Fasenra. The IgE or EGPA criterion is either pretreatment serum IgE of at least 30 IU/mL with documented inadequate response or an intolerable adverse event with Xolair, pretreatment serum IgE less than 30 IU/mL, or EGPA with documented inadequate response or an intolerable adverse event with Fasenra.Covered when either pathway is met
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Asthma
    Policy CodePolicy 4659-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when seeking an exception to preferred-product step therapy for a non-preferred asthma product.
    SourceLink
    On This Page
    Applicable Coverage CriteriaClinical Thresholds and TimingAuthorization and Documentation RequirementsPolicy ScopeUtilization Management TermsInitial Therapy for Non-Preferred ProductsContinuation or Recent-Use PathwayPreferred-Product Sequencing
  1. IgE less than 30 IU/mL: Pretreatment serum IgE is less than 30 IU/mL.less than 30 IU/mL
  2. Age/preferred-product and IgE or EGPA pathway

    • Age and preferred-product criterion

      • Age 12 or older with Fasenra and Tezspire failure or intolerance: Member is 12 years of age and older and has documented inadequate response or intolerable adverse event with both Fasenra and Tezspire.12 years and older
      • Age under 12 with Fasenra failure or intolerance: Member is less than 12 years of age and has documented inadequate response or intolerable adverse event with Fasenra.less than 12 years
    • Serum IgE or EGPA criterion

      • IgE at least 30 IU/mL with Xolair failure or intolerance: Pretreatment serum IgE is at least 30 IU/mL and the member has documented inadequate response or intolerable adverse event with Xolair.at least 30 IU/mL
      • IgE less than 30 IU/mL: Pretreatment serum IgE is less than 30 IU/mL.less than 30 IU/mL
      • EGPA with Fasenra failure or intolerance: Member has a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) and documented inadequate response or intolerable adverse event with Fasenra.
  3. Age threshold for Nucala exception
    Age threshold 112 years of age and older
    Age threshold 2Less than 12 years
    ApplicationDetermines whether the Nucala exception requires inadequate response or an intolerable adverse event with both Fasenra and Tezspire, or with Fasenra alone
    Step Therapy

    Follow the Preferred-Product Sequence

    Use the preferred-product sequence before requesting a non-preferred product, unless the member meets an applicable clinical exception. Confirm which product is preferred under the plan and document the member’s relevant treatment history.

    • Preferred: Fasenra (benralizumab), Tezspire (tezepelumab-ekko), and Xolair (omalizumab).
    • Non-preferred: Cinqair (reslizumab) and Nucala (mepolizumab).

    Unsupported block type: billing_rule

    Documentation Required

    Document the Clinical Exception

    Document the clinical circumstances supporting an exception request, including recent treatment and the member’s response or tolerance. Records should clearly identify the products tried, dates or recency of treatment, and the applicable clinical findings.

    • Document prior treatment with Cinqair or Nucala within the past 365 days when applicable.
    • For Cinqair, document inadequate response or an intolerable adverse event with both Fasenra and Tezspire, and address the applicable Xolair and pretreatment serum IgE criterion.
    • For Nucala, document the applicable age, nasal-polyps or EGPA diagnosis, pretreatment serum IgE, and inadequate response or intolerable adverse event criteria involving Fasenra, Tezspire, or Xolair.
    Denial Risk

    Non-Preferred Requests Without an Exception May Be Denied

    Coverage for a non-preferred product may be denied when the request does not establish an applicable clinical exception. Ensure the submitted documentation supports at least one qualifying pathway for the requested product.

    • Cinqair requires either treatment within the past 365 days or the specified inadequate-response or intolerable-adverse-event and IgE criteria.
    • Nucala requires either treatment within the past 365 days or the applicable comorbidity, age, EGPA, inadequate-response or intolerable-adverse-event, and IgE criteria.
    • Incomplete documentation or failure to meet the applicable criteria may result in denial.
    May include previous use of the requested product
  4. IgE at least 30 IU/mL with Xolair failure or intolerance: Pretreatment serum IgE is at least 30 IU/mL and the member has documented inadequate response or intolerable adverse event with Xolair.at least 30 IU/mL
  5. IgE less than 30 IU/mL: Pretreatment serum IgE is less than 30 IU/mL.less than 30 IU/mL
  6. Nucala

    Coverage for Nucala is provided when either of the following criteria is met.

    Nucala initial coverage

    • Recent Nucala treatment: Member has received treatment with Nucala in the past 365 days.past 365 days
    • Clinical exception pathways

      • Nasal polyps pathway

        • IgE/Xolair pathway

          • IgE at least 30 IU/mL with Xolair failure or intolerance: Pretreatment serum IgE is at least 30 IU/mL and the member has documented inadequate response or intolerable adverse event with Xolair.at least 30 IU/mL
          • IgE less than 30 IU/mL: Pretreatment serum IgE is less than 30 IU/mL.less than 30 IU/mL
      • Age/preferred-product and IgE or EGPA pathway

        • Age and preferred-product criterion

          • Age 12 or older with Fasenra and Tezspire failure or intolerance: Member is 12 years of age and older and has documented inadequate response or intolerable adverse event with both Fasenra and Tezspire.12 years and older
          • Age under 12 with Fasenra failure or intolerance: Member is less than 12 years of age and has documented inadequate response or intolerable adverse event with Fasenra.less than 12 years
        • Serum IgE or EGPA criterion

          • IgE at least 30 IU/mL with Xolair failure or intolerance: Pretreatment serum IgE is at least 30 IU/mL and the member has documented inadequate response or intolerable adverse event with Xolair.
    at least 30 IU/mL
  7. IgE less than 30 IU/mL: Pretreatment serum IgE is less than 30 IU/mL.less than 30 IU/mL
  8. EGPA with Fasenra failure or intolerance: Member has a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) and documented inadequate response or intolerable adverse event with Fasenra.